Research programme: oncolytic virus - TILT Biotherapeutics

Drug Profile

Research programme: oncolytic virus - TILT Biotherapeutics

Alternative Names: Adv-5/3-d24-TNF-IL2; O-Ad; TILT-123; TILT-234; TILT-321

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator TILT Biotherapeutics
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Dec 2016 TILT Biotherapeutics plans a phase I trial for Malignant melanoma in Europe
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Cancer presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top